Compare GPRE & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | MRVI |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 1.0B |
| IPO Year | 2004 | 2020 |
| Metric | GPRE | MRVI |
|---|---|---|
| Price | $16.57 | $6.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $12.57 | $4.13 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,091,680,000.00 | $185,743,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | $11.85 | $7.87 |
| P/E Ratio | $40.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.08 | $1.99 |
| 52 Week High | $19.65 | $7.44 |
| Indicator | GPRE | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 60.17 |
| Support Level | $14.01 | $5.67 |
| Resistance Level | $19.29 | N/A |
| Average True Range (ATR) | 0.93 | 0.36 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 19.95 | 57.91 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.